英文药名: Singulair(montelukast chewable tablets)
中文药名: 顺尔宁（孟鲁司特咀嚼片）
生产品牌药厂家: Merck Frosst
药品名称和成分
顺尔宁（孟鲁司特）
英文名: Montelukast Sodium
主要成分：孟鲁司特钠。
适应症
成人和2岁及2岁以上儿童哮喘的预防和长期治疗，包括预防白天和夜间的哮喘症状，治疗对阿司匹林敏感的哮喘患者以及预防运动引起的支气管收缩；也用于减轻季节性过敏性鼻炎引起的症状。
用法用量
哮喘 每日1次睡前服用，季节性过敏性鼻炎 酌情在需要时间服药。15岁及以上患者 每次10 mg。6-14岁患者 每次5 mg。2-5岁患者 每次4 mg。
如果您有任何疑问，请遵医嘱。
不良反应
成人可见腹痛和头痛；儿童可见头痛。
注意事项
不应用于治疗急性哮喘发作。孕妇及哺乳妇女慎用。
规格
咀嚼片:4mg; 片剂:5mg, 10mg; 口服颗粒:4mg; 小儿咀嚼片:5mg.
FORMULATION:
Each 4mg chewable tablet contains 4.2mg montelukast (as sodium) equivalent to 4mg montelukast.
Each 5mg chewable tablet contains 5.2mg montelukast (as sodium) equivalent to 5mg montelukast.
Each 10mg film-coated tablet contains 10.4mg montelukast (as sodium) equivalent to 10mg montelukast.
INDICATIONS
Montelukast (Montemax) is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age or older.
Montelukast (Montemax) is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older) and perennial allergic rhinitis in adults and pediatric patients in 6 months of age and older.
DOSAGE AND ADMINISTRATION:
Montelukast (Montemax) should be taken once daily. For asthma the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
Adults and 15 years and older with asthma and allergic rhinitis: 10mg tablet daily.
Patients below 15 years old with asthma and allergic rhinitis: one 5mg chewable tablet daily. No dosage adjustment within this age group is necessary.
Children between 2 to 5 years old with asthma and allergic rhinitis: one 4mg chewable tablet daily.
INTERACTIONS:
Clinical monitoring when montelukast is administered with a potent hepatic enzyme inducers such as phenytoin, Phenobarbital, or rifampicin.
PHARMACOKINETICS:
Peak plasma concentrations of montelukast are achieved in 2 to 4 hours after oral administration. The mean oral bioavailability is 64%. Montelukast is more than 99% bound to plasma proteins. It is extensively metabolized by cytochrome P450 isoenzymes CYP3A4, CYP2A6 and CYP2C9 and is excreted principally in faeces via the bile, Metabolism was reduced and the elimination half-life prolonged in patients with mild to moderate hepatic impairment.
CAUTION:
Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
ADVERSE REACTIONS:
Edema, agitation and restlessness, allergy including anaphylaxis, angioedema and urticaria, chest pain, tremor, dry mouth, vertigo and arthralgia.
USE IN PREGNANCY AND LACTATION
There is no adequate and well-controlled studies in pregnant women, therefore, montelukast should be used during pregnancy only if clearly needed. It is not known if montelukast is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when montelukast is given to a nursing mother.
USE IN ELDERLY:
No overall differences in safety or effectiveness were observed between the elderly and the younger persons, but greater sensitivity of some other individuals cannot be ruled out.
CONTRAINDICATIONS:
Hypersensitivity to any component of Montemax.
AVAILABILITY:
Tablet 4mg chewable: box of 28s in blisters
Tablet 5mg chewable: box of 28's in blisters
Tablet 10mg film-coated: box of 30's in blisters
Store at Temperatures not Exceeding 30oC Protect form Moisture and Light